Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astonea LabsBOM:544409 +1.01%12 FCF Yield % is -9.60 as of Jul. 30, 2026. GuruFocus rates BOM:544409 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Astonea Labs ranks worse than 80.73% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Astonea Labs FCF Yield % Related Terms
Astonea Labs FCF Yield % Historical Data
* Premium members only.
The historical data trend for Astonea Labs's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Astonea Labs's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astonea Labs FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astonea Labs's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Astonea Labs's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astonea Labs (BOM:544409) has a FCF Yield % of -9.60 as of Jul. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Astonea Labs and its competitors. According to the industry distribution chart, Astonea Labs ranks #813 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 80.7%.
Is Astonea Labs' FCF Yield % too high?
Astonea Labs' current FCF Yield % is -9.60. Based on the distribution chart, Astonea Labs ranks #813 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Astonea Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Astonea Labs' FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Astonea Labs ranks #813 out of 1007 companies for FCF Yield %. This places Astonea Labs in the lower half of its industry. The industry median FCF Yield % is 0.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.76, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Astonea Labs and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astonea Labs's current FCF Yield % is -9.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astonea Labs stock overvalued right now?
Astonea Labs (BOM:544409) has a current FCF Yield % of -9.60. The current FCF Yield % is -9.60. Astonea Labs' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Astonea Labs (BOM:544409), the current FCF Yield % is -9.60 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Astonea Labs Ltd is an India-based pharmaceutical and cosmetics company engaged in the manufacturing and development of healthcare and personal care products. The Company operates in the pharmaceuticals and cosmetics & personal care space, offering products that include generic medicines, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as skincare, haircare, anti-aging, ethical, and organic cosmetic products, supported by in-house research and development and contract manufacturing services. Its business activities are organized across key segments comprising Pharmaceuticals, Cosmetics & Personal Care, R&D & Innovation, and Contract Manufacturing (CDMO).
12GF Score
Get the complete analysis for BOM:544409
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544409 has been successfully added to your 
